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ABSTRACT
Testicular germ cell tumors (TGCTs) are the most common cancers of young 
males. A substantial portion of TGCT patients are refractory to cisplatin. There are no 
effective therapies for these patients, many of whom die from progressive disease. 
Embryonal carcinoma (EC) are the stem cells of TGCTs. In prior in vitro studies we 
found that EC cells were highly sensitive to the DNA methyltransferase inhibitor, 5-aza 
deoxycytidine (5-aza). Here, as an initial step in bringing demethylation therapy to the 
clinic for TGCT patients, we evaluated the effects of the clinically optimized, second 
generation demethylating agent guadecitabine (SGI-110) on EC cells in an animal 
model of cisplatin refractory testicular cancer. EC cells were exquisitely sensitive 
to guadecitabine and the hypersensitivity was dependent on high levels of DNA 
methyltransferase 3B.  Guadecitabine mediated transcriptional reprogramming of 
EC cells included induction of p53 targets and repression of pluripotency genes.  As a 
single agent, guadecitabine completely abolished progression and induced complete 
regression of cisplatin resistant EC xenografts even at doses well below those required 
to impact somatic solid tumors. Low dose guadecitabine also sensitized refractory 
EC cells to cisplatin in vivo. Genome-wide analysis indicated that in vivo antitumor 
activity was associated with activation of p53 and immune-related pathways and the 
antitumor effects of guadecitabine were dependent on p53, a gene rarely mutated in 
TGCTs. These preclinical findings suggest that guadecitabine alone or in combination 
with cisplatin is a promising strategy to treat refractory TGCT patients.
INTRODUCTION
Testicular germ cell tumors (TGCTs) are the 
most common cancer in men 15 to 35 with increasing 
incidence in the last 30 years [1]. Testicular cancer 
patients are successfully treated with a combination of 
cisplatin, bleomycin and etoposide [2, 3]. However, 
15–20% of all patients and 50% of patients with poor-risk 
disease are refractory to treatment and many eventually 
die from progressive disease [4–6]. Further, there are 
patients who initially respond to therapy but undergo late 
relapse. These patients are rarely cured if their disease is 
not amenable to surgical resection [7, 8]. Therapies to treat 
the cisplatin resistant population is a major un-met clinical 
need. Unlike most other cancers, morbidity and mortality 
due to testicular cancer occurs during the most productive 
years of a patient’s life. An average of more than 35 years of 
life is lost when a testicular cancer death occurs, well over 
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a decade longer than any other adult malignancy. Further, 
there is a need to reduce co-morbidities and the burden of 
therapy-related toxicities and survivorship issues [9–10]. 
TGCTs consist of two histologically distinct 
subtypes: seminomas (40%) and nonseminomas (60%). 
Nonseminomas are further divided into embryonal 
carcinoma (EC), teratoma, yolk sac tumor and 
choriocarcinoma [11]. TGCTs are thought to arise from 
transformation of primordial germ cells and pluripotent 
EC represents the stem cell component of nonseminoma 
and can differentiate into mature nonseminoma subtypes 
[12]. One of the unique features of TGCTs is distinct 
genome-wide DNA methylation compared to somatic solid 
tumors that is proposed to be linked to their pluripotent 
nature and primordial germ cell origins. Most human 
cancers have global DNA hypomethylation coupled 
with hypermethylation of CpG islands at specific tumor 
suppressor gene promoters [13]. Seminomas appear to 
have greatly reduced levels of overall DNA methylation as 
compared to adult somatic tumors while nonseminomas and 
EC possess intermediate levels of DNA methylation [14, 15]. 
DNA methylation is maintained primarily by 
the DNA methyltransferase, DNMT1, while de novo 
DNA methylation is mediated primarily by DNMT3A 
and DNMT3B [16]. The nucleoside analogs 5-aza-
deoxcytidine (referred to here as 5-aza) and 5-aza-cytidine 
are potent DNA methyltransferase inhibitors (DNMTIs) 
[17]. We showed that EC cells are highly sensitive to 
low concentrations of 5-aza in vitro [18]. This sensitivity 
appeared to partially dependent on high expression of the 
pluripotency-associated methyltransferase, DNMT3B [18]. 
In the current study, we evaluate the effects of the 
clinically and pharmacological optimized demethylating 
agent guadecitabine (SGI-110) on EC cells and in an 
animal model of cisplatin refractory nonseminoma 
testicular cancer [19]. EC-derived cisplatin resistant cells 
and tumors were highly sensitive to guadecitabine and 
in vivo guadecitabine was also able to sensitize cisplatin 
resistant tumors to cisplatin.  Further, we demonstrate 
that these antitumor effects are highly associated with 
activation of p53, a gene rarely mutated in TGCTs. 
Interestingly, immune pathway genes were also induced 
in EC tumors by guadecitabine, suggesting that tumor 
immune activation could enhance antitumor activity in the 
clinic. Together our findings provide strong rationale for 
further development of guadecitabine as a novel therapy 
to treat patients with cisplatin-refractory testicular cancer. 
RESULTS
Cisplatin sensitive and resistant EC cells are highly 
sensitive to low concentrations of guadecitabine in 
a DNMT3B-dependent manner 
We previously demonstrated that a variety of 
TGCT-derived EC cells lines are highly sensitive to low 
nanomolar concentrations of 5-aza [18]. However, 5-aza 
and other DNA methylation inhibitors (DNMTIs) are 
subject to rapid degradation by hydrolytic cleavage and 
deamination necessitating chronic intravenous infusion 
[20]. In anticipation of potential clinical assessment 
of demethylation therapy for TGCTs we assessed the 
effects of the second generation demethylating agent 
guadecitabine that is not subject to the same metabolism 
as other DNMTIs and can be given subcutaneously with 
a longer effective half-life and a more extended exposure 
window compared to 5-aza [19]. Cisplatin sensitive EC 
cells, NT2/D1 and cisplatin resistant NT2/D1-R1 cells 
were highly sensitive to guadecitabine with an IC-50 
of 5 nM (Figure 1A). This is in contrast to the effects 
of guadecitabine on somatic solid tumor cells HCT116, 
U20S and MCF7 that were relatively insensitive to 
guadecitabine at concentrations as high at 1 µM. Further, 
pretreatment of cisplatin resistant NT2/D1-R1 cells with 
low concentrations of guadecitabine resensitized the 
cells to cisplatin (Figure 1B). In this experiment cells 
pretreated with guadecitabine were allowed to recover 
before treating with cisplatin such that the cells had 
a comparable growth rate to cells not pretreated with 
guadecitabine.  We have linked 5-aza hypersensitivity 
in EC cells to high levels of the DNA methyltransferase, 
DNMT3B and provided evidence to suggest that the 
relative insensitivity of somatic cancer cells to 5-aza is 
due to low DNA methyltransferase levels and activity 
[18]. The sensitivity of cisplatin sensitive and resistant EC 
cells to guadecitabine was highly dependent on DNMT3B 
as DNMT3B knockdown results in robust guadecitabine 
resistance in NT2/D1 and NT2/D1-R1 cells (Figure 2). 
These data suggest that EC cells are exquisitely sensitive 
to the novel DNMTI guadecitabine, in part due to high 
levels of DNMT3B. 
Low concentrations of guadecitabine 
transcriptionally reprograms cisplatin sensitive 
and resistant EC cells
We assessed expression of genes determined to 
be target genes of 5-aza in EC cells. P53 target genes 
GDF15, p21 and GADD45A were induced in response 
to guadecitabine while the pluripotency gene NANOG 
was repressed in both NT2/D1 and NT2/D1-R1 cells 
(Figure 3). In addition, a gene known to be highly 
methylated in TGCTs, RASSF1, and a gene we identified as 
a novel methylated gene in EC cells, SOX15 [21], were both 
induced with 5-aza and guadecitabine (Figure 3). Taken 
together these data strongly suggest guadecitabine potently 
suppresses the in vitro proliferation and survival of EC cells 
at low nanomolar concentrations in a manner similar to 
5-aza [18, 21]. It is of note that our data does not prove 
that the identified gene expression changes are responsible 
for the anti-proliferation and anti-survival activity of 
guadecitabine, which will require detailed follow-up studies. 
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Guadecitabine displays potent antitumor effects 
in vivo toward cisplatin resistant EC
In myelodysplastic syndrome (MDS) and in 
recent trials in lung and ovarian cancer, lower than 
maximum tolerated doses of demethylating agents 
have shown improved efficacy [22–25]. However, our 
data suggests that TGCTs may be uniquely sensitive to 
even lower doses of DNMTIs. To examine the in vivo 
effects of guadecitabine on EC cells we established 
cisplatin resistant tumors in mice. Mice were treated by 
subcutaneous injections with either 2 mg/kg guadecitabine 
or vehicle control for 5 days per week for 2 weeks once 
palpable tumors were observed.  This is a “low” dose 
of guadecitabine that only modestly effects ovarian 
and liver cancer xenograft progression using a similar 
treatment schedule [26, 27]. This dose of guadecitabine 
completely abrogated tumor growth and caused complete 
tumor regression that was evident up to three weeks after 
treatment cessation (Figure 4A). This treatment resulted 
in no whole animal toxicity as assessed by body weight 
(Figure 4C). While no tumor was evident in most mice 
treated with guadecitabine at this dose, occasionally it was 
noted that a small avascular mass was present at the cell 
injection site that did not progress even when treatment 
was stopped for 4 weeks (Figure 4B). Preliminary 
histological analysis indicated that these cells represented 
differentiated yolk sac and teratoma (not shown).   In 
contrast, control tumors were large, highly vascular and 
comprised mainly of undifferentiated EC cells that often 
invaded skeletal muscle (Figure 4B and data not shown).  
In order to ascertain whether guadecitabine is 
effective in suppressing EC tumor cell growth at even 
lower doses, the effect of 2.5 mg/kg guadecitabine and 
two, five-fold dose de-escalations of guadecitabine were 
compared.  Guadecitabine was highly effective at inducing 
complete regression and inhibition of EC tumor growth 
even at doses of 0.5 and 0.1 mg/kg and was effective in 
regressing large tumors (Figure 4D). However, it was 
noted that compared to the 2.0 and 2.5 mg/kg doses, some 
tumors at the 0.5 and 0.1 mg/kg doses began to grow back 
beginning at 2 weeks post therapy (Figure 4D). 
Since pretreatment of cisplatin resistant EC cells with 
low concentrations of quadecitabine resensitized the cells 
to cisplatin treatment we assessed whether this also occurs 
in vivo. The growth of the cisplatin resistant tumors after 
only one cycle (5 days) of 0.5 mg/kg guadecitabine alone 
or followed by a single 9.0 mg/kg dose of cisplatin was 
compared.  While treatment with guadecitabine at 0.5 mg/kg 
alone resulted in incomplete tumor inhibition and regrowth, 
Figure 1: EC cells are highly sensitive to low concentrations of guadecitabine. (A) Cisplatin sensitive EC cells, NT2/D1, 
and cisplatin resistant cells, NT2/D1-R1, but not HCT116 colon cancer cells, U2OS osteosarcoma cells, or MCF7 breast cancer cells 
are sensitive to low concentrations of guadecitabine. Guadecitabine was added for 3 days to exponentially growing cultures. Viable cell 
growth and survival were measured. All data points are the average of biological triplicates. Error bars are standard deviation. *p < 0.01 
comparing drug treatments to vehicle control in the same cell line. (B) Pretreatment with low concentrations of guadecitabine restores 
cisplatin sensitivity to cisplatin resistant EC cells. NT2/D1-R1 cells were pretreated with vehicle or 10 nM guadecitabine for 3 days before 
replating and a 48-hour recovery period followed by indicated cisplatin treatments for 6 hours. Cell viability was measured 3 days later. 
All data points are the average of biological triplicates.  Error bars are standard deviation.  *p < 0.01 comparing NTD1-R1 to NT2D1-R1 + 
guadecitabine. Experiments were repeated twice with similar results. 
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Figure 2: Guadecitabine and 5-aza sensitivity in EC cells are dependent on DNMT3B. DNMT3B knockdown results 
in resistance to guadecitabine and 5-aza in (A) NT2/D1 and (B) NT2/D1-R1 cells. Guadecitabine or 5-aza was added for 3 days to 
exponentially growing cultures. Viable cell growth and survival were measured. All data points are the average of biological triplicates. 
Error bars are standard deviation. *p < 0.01 and **p < 0.05 comparing control cell lines with their corresponding shDNMT3B cells. Right, 
The shDNMT3B cells were previously characterized and have a knockdown at the protein level of greater than 90% (18) and knockdown 
was further confirmed by real-time PCR assays. Error bars are standard deviation. *p < 0.01 comparing control cell lines with their 
corresponding shDNMT3B cells. Experiments were repeated twice with similar results.
Figure 3: Guadecitabine and 5-aza remodel gene transcription in EC cells. (A) NT2/D1 and (B) NT2/D1-R1 cells were treated 
with 10 nM 5-aza or guadecitabine for 3 days and RNA was harvested for real-time PCR analysis.  Each bar represents the average of 
3 biological replicates. Error bars are standard deviation. *p < 0.01 and **p < 0.05 comparing each drug treatment to vehicle treatment. 
Experiments were repeated twice with similar results.
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addition of cisplatin 2 days later resulted in complete and 
lasting regression of the tumors with no evident toxicity 
(Figure 4E). This is in contrast to what occurs with two 
consecutive 9.0 mg/kg injections of cisplatin alone, which 
resulted in either tumor progression, regrowth or lethal 
toxicity (Figure 4E). Thus the combination of very low dose 
guadecitabine and cisplatin is more effective than either 
treatment alone. 
In vivo tumor response is associated with genome 
wide induction of p53 target and immune-related 
gene signatures
We conducted microarray-based gene expression 
analysis to compare gene expression changes between 
control tumors and tumors after only 4 days of 1.5 mg/kg 
guadecitabine treatment. At this time point guadecitabine 
treated tumors have not yet begun to regress in size 
compared to control tumors (Figure 4A). Gene set 
enrichment analysis (GSEA) indicated that guadecitabine 
treated tumors induced expression of p53 target genes 
and related pathways and pathways associated with DNA 
methylation (Figure 5). However, guadecitabine treated 
xenografts also were strongly enriched for immune-
related gene signatures (Figure 5). This includes signatures 
associated with TNF, allograft rejection, HLA class C 
and interferon signaling.  Examination of the leading 
edge genes indicated that these enriched signatures were 
driven largely by induction of HLA class I and NFKB 
pathway genes (Figure 6A). DNA demethylating agents 
Figure 4: Guadecitabine potently inhibits growth and induces regression of cisplatin resistant EC tumors in vivo. 
(A) Mice bearing cisplatin resistant tumors were randomized to subcutaneous injections of guadecitabine at a dose of 2.0 mg/kg or vehicle 
control. Randomization and injections were performed when palpable tumors were just evident. Treatments were for 5 days per week for 
2 weeks. Each line represents a single mouse (7 vehicle treated, 7 guadecitabine treated). (B) Representative tumors from the experiment 
in A. In most cases, tumors completely regressed after guadecitabine therapy while in a few cases a residual remnant tumor remained. 
(C) Treatment of 2.0 mg/kg guadecitabine for 5 days per week for 2 weeks did not effect whole body weight. Measurements began on 
the day after the first guadecitabine injection. (D) Mice bearing cisplatin resistant tumors were randomized to vehicle control or indicated 
dosages of guadecitabine for 5 days per week for 2 weeks.  Each line represents a single mouse (3 mice per group). Note: some tumors were 
larger than just palpable size at the start of therapy and still regressed completely with guadecitabine; however, one mouse at the lowest, 
0.1 mg/kg dose had only a partial response. (E) Low dose guadecitabine and cisplatin combination therapy is effective for cisplatin resistant 
EC cells. Mice bearing cisplatin resistant tumors were randomized to 3 groups.  Guadecitabine alone at a dose of 0.5 mg/kg for 5 days for 
only 1 week, guadecitabine at a dose of 0.5 mg/kg for 5 days followed two days later with a single dose of 9 mg/kg cisplatin, or two doses of 
9 mg/kg cisplatin on consecutive days. Each line represents a single mouse (4 mice per group). Note that two-dose cisplatin treatment alone 
resulted in lethal toxicity in two mice on day 12. No overt toxicity was seen in guadecitabine or guadecitabine + single dose cisplatin groups.
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have recently been associated with enhancing anti-tumor 
immunity (28–30). Our data suggests an alternative 
mechanism of guadecitabine action that may be clinically 
relevant for the treatment of refractory TGCTs.  In this 
regard, we demonstrated that guadecitabine induced 
the expression of cancer testis antigens MAGE-A3 and 
MAGE-A1 in cisplatin resistant EC cells (Figure 6B). 
Low concentration guadecitabine response in 
cisplatin sensitive and resistant EC is dependent 
on p53
Since both 5-aza and guadecitabine induce the 
expression of p53 target genes, the importance of p53 in 
guadecitabine mediated repression of cell proliferation 
and survival was assessed. Knockdown of p53 in NT2/
D1 and NT2/D1-R1 cells resulted in relative guadecitabine 
resistance which demonstrates that activation of p53 is 
important for guadecitabine sensitivity of testicular cancer 
cells (Figure 7A and 7B).
DISCUSSION 
Acquired resistance to chemotherapy and targeted 
therapy is currently the single most important impediment 
to curative treatments of advanced cancers. Due in 
part to advances in our understanding of epigenetic 
deregulations in cancer, there has been a recent revisiting 
of the concept of demethylation therapy, especially the 
use of demethylation inhibitors to resensitize refractory 
cancers to no-longer effective therapies [26, 27, 31]. Here 
we demonstrate that refractory testicular cancer may be 
particularly sensitive to demethylation therapy.  Testicular 
cancer cells, even those resistant to cisplatin, were highly 
Figure 5: Guadecitabine induces p53 and immune pathway gene expression signatures in EC tumors in vivo. GSEA 
analysis of tumors treated in vivo for 4 days with 1.5 mg/kg guadecitabine (SGI-110) in biological triplicate revealed that the top gene sets 
enriched in response to guadecitabine are related to immune or p53 pathway activation. NES is Normalized Enrichment Score. 
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sensitive to low concentrations of the novel demethylating 
agent, guadecitabine.  Cisplatin resistant TGCT-derived 
EC were highly sensitive to guadecitabine in vitro and 
in vivo and guadecitabine was also able to sensitize 
cisplatin resistant tumors to cisplatin. Strikingly, as a single 
agent extremely low doses of guadecitabine completely 
abolished progression and induced complete regression 
of cisplatin resistant EC tumors.  Mechanistically we 
demonstrate that these potent antitumor effects of 
guadecitabine are dependent on DNMT3B and also p53. In 
de novo, genome-wide analysis, we provide evidence that 
guadecitabine induces early and extensive p53 pathway 
activation in vivo and interestingly also induces immune 
tumor cell recognition components including HLA class I 
and cancer testis antigens. Based on the preclinical studies 
reported here, we suggest that guadecitabine and other 
demethylation inhibitors may provide a path to overcome 
acquired drug resistance in testicular cancer, laying a 
foundation and strong rationale for testing this class of 
epigenetic drugs in the clinical setting. 
Demethylation therapy with 5-aza is approved for 
the treatment of myelodysplasitic syndrome (MDS) and 
5-aza is currently under clinical evaluation for specific 
leukemia and solid tumors [19, 22–25]. Recent experience 
with MDS suggests that demethylating agents should be 
given below the maximum tolerated dose and over many 
cycles [22]. The scientific basis for lower dose therapy 
relates to the mechanism of demethylation mediated by 
the nucleoside analog class of DNMTIs which require 
incorporation into newly synthesized DNA in contrast to 
the non-specific toxicity and repression of cell division 
that occurs at higher doses [17]. This may explain past 
unsuccessful experiences with demethylation inhibitors 
given at maximum tolerated doses for solid tumors [31]. 
For example, a clinical trial using 5-aza-cytidine to treat 
refractory testicular cancer was unsuccessful in improving 
outcomes [32]. However, in this trial 5-aza-cytidine was 
used at high doses as a non-specific cytotoxic agent and 
not at the low doses that are optimal to inhibit DNA 
methylation.  The trial also did not test whether DNMTI 
therapy could sensitize refractory TGCTs to cisplatin 
[32]. Recent studies have also suggested that lower 
“biologically effective” doses of 5-aza may be an effective 
clinical strategy to target tumor-initiating cells in solid 
tumors [23, 24, 33].
Our data demonstrates that testicular cancer cells 
are uniquely sensitive to extremely low doses of DNMTIs 
suggesting that these agents can potentially be used at 
doses with very little toxicity. At first glance it may seem 
paradoxical that EC cells are highly sensitive to DNA 
methylation inhibitors but resistant to these inhibitors 
when one of its targets, DNMT3B is depleted.  This may 
be related to incorporation of 5-aza into newly synthesized 
DNA when given at low doses resulting in DNMT3B-
DNA adduct formation. More studies are required to better 
define the nature of the DNMT3B-dependent sensitivity of 
EC cells to demethylating agents. 
The mechanism to account for the sensitivity of 
EC cells to DNMTs is unclear but is likely related to the 
germ cell origins of TGCTs [3, 34]. Seminomas have 
Figure 6: Guadecitabine induces HLA, NFKB and cancer testis antigens in EC tumors. (A) Microarray results for HLA class 
I and NFKB pathway genes. (B) Real-time PCR analysis of cancer testis antigens IMAGE-A3, IMAGE-A1 and NFKB gene, NFKBIA. 
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very little DNA methylation compared to normal cells 
and somatic tumors while nonseminomas and EC have an 
intermediate level and there is some evidence to suggest 
an association between cisplatin resistance in TGCTs 
and increased methylation of candidate tumor suppressor 
genes [14, 15, 35–37]. In addition, teratomas are heavily 
methylated and resistant to cisplatin.   We show here that 
multiple downstream mechanisms appear to be engaged 
in the antitumor effect of low concentration guadecitabine 
in testicular tumors including activation of p53 and 
repression of pluripotency gene expression.
DNMTIs such as 5-aza are subject to rapid 
degradation by hydrolytic cleavage and deamination by 
cytidine deaminase and are unstable after intravenous 
infusion, limiting their potential as cancer therapeutics 
[20]. Guadecitabine is a dinucleotide comprised of 
guanosine and decitabine linked by a phosphodiester bond. 
Guadecitabine is largely resistant to cytidine deaminase 
degradation resulting in prolonged in vivo drug exposure 
following small volume subcutaneous administration [19]. 
This DNMTI was shown to achieve hypomethylation and 
was well tolerated in primates [38]. In a phase I/II trial in 
acute myeloid leukemia and MDS patients, guadecitabine 
was shown to be better tolerated and demonstrated activity 
in patients who had progressed on 5-aza [19]. While 5-aza 
is unstable and given intravenously, guadecitabine given 
subcutaneously has a longer effective half-life and a more 
extended exposure window compared to intravenous 
infusion of 5-aza [19]. 
Aberrant DNA hypermethylation down-regulates 
the expression of components of the “tumor recognition 
complex” including HLA class I, tumor-associated antigen, 
cancer testis antigens and accessory/co-stimulatory 
molecules in neoplastic cells including cutaneous 
melanoma and sarcoma cancer cells and DNMTIs have 
been shown to induce the expression of some of these 
components. [28–30]. In the current study we provide 
evidence that guadecitabine induces immune signatures 
including induction of HLA class I, cancer testis antigens 
and the NFKB pathway in EC tumors. The contribution 
of this activation to the dramatic antitumor effects of 
guadecitabine in immune-compromised mice is likely 
minor but suggests that enhanced immune recognition of 
human TGCTs may be an additional beneficial feature of 
guadecitabine therapy in the clinic.
While the testis is thought to be an immune 
privileged site, the major clinical problem for testicular 
cancer is metastatic disease. Whether immune privilege 
Figure 7: Guadecitabine and 5-aza sensitivity in EC cells is dependent on p53. Knockdown of p53 results in resistance to 
(A) Guadecitabine in NT2/D1 cells and (B) 5-aza in NT2/D1-R1 cells.  Guadecitabine or 5-aza was added for 3 days to exponentially 
growing cultures. Viable cell growth and survival were measured. All data points are the average of biological triplicates. Error bars 
are standard deviation. *p < 0.01 comparing control cell lines with their corresponding shp53 cells. Right, The shp53 knockdown was 
confirmed by real-time PCR assays.  Error bars are standard deviation. *p < 0.01 comparing control cell lines with their corresponding 
shp53 cells.  Western blot showing robust knockdown of p53 in sh-p53 NT2/D1 cells is also included. A similar level of knockdown was 
also seen in NT2/D1-R1 cells (not shown). Experiments were repeated with similar results.
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in the testis is mediated primarily by structural features 
within the testis itself or due to immune tolerance that may 
persist and extend to testicular cancer cells outside the 
testis is not known. More studies are needed to determine 
whether immune privilege would be an impediment to 
immune-based therapies for metastatic testicular cancer 
and whether induction of HLA class I and cancer testis 
antigens by quadecitabine could break this immune 
tolerance if it exists. 
In summary, the in vitro and in vivo preclinical 
findings in this report demonstrating the striking and 
potent activity of guadecitabine in TGCT cells strongly 
supports further investigation of DNMTI-based therapies 
for the treatment of testicular cancer.  The progression 
of this basic science discovery to a clinical setting using 
guadecitabine to sensitize cisplatin refractory TGCTs is 
currently underway in the form of an open label proof 
of concept phase I study we are currently conducting 
(NCT02429466).
MATERIALS AND METHODS
Cell culture and drug treatments
All cell lines were cultured in DMEM media with 
10% fetal bovine serum supplement plus glutamine 
and antibiotics. Cells were treated with the indicated 
concentrations of 5-aza-deoxycytidine (5-aza) or 
guadecitabine (SGI-110) for 3 days with drug replenished 
each day.  Cisplatin treatments were performed at the 
concentrations and time points indicated.  To assess cell 
proliferation and survival, Cell-Titre Glo (Promega) 
assays were performed.   Guadecitabine was provided by 
Astex Pharmaceuticals.   All other drugs and chemicals 
were purchased from Sigma.  HCT116 (colon cancer), 
U20S (osteosarcoma) MCF7 (breast cancer) and NT2/
D1 (embryonal carcinoma) cells were obtained from 
the American Type Culture Collection (ATCC) and 
authenticated by the ATCC with karyotyping and/or short 
tandem repeat (STR) profiling. NT2/D1-R1 cells are 10-
fold resistant to cisplatin and their characterization and 
derivation have been previously described [39]. Cells 
were frozen within 1 month of purchase and used within 2 
months after resuscitation. NT2/D1-R1 cells were frozen 
within 2 months of derivation and used within 2 months 
after resuscitation.
Lentiviral shRNA production
NT2/D1-sh84 and NT2/D1-R1-sh84 cells with stable 
lentiviral silencing of DNMT3B were previously described 
and have a knockdown of DNMT3B of greater than 90% at 
the protein level [18]. Lentiviral silencing shRNA targeting 
p53 (TRCN0000010814) was purchased from Thermo 
Fisher Scientific along with TRC lentiviral non-targeting 
shRNA control (RHS6848). The sequence of shp53 is 
GAGGGATGTTTGGGAGATGTA. Lentiviral stocks were 
generated from 293T cells as previously described [18]. 
Cells were cultured with lentiviral stocks for 24 hours and 
stable pools were selected with 1.0 μg/mL puromycin. 
Real-time PCR analysis
Generation of cDNA was performed with the High 
Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Real-time polymerase chain reaction (PCR) 
assays were performed with iTaq Universal SYBR Green 
Supermix (Bio-Rad Laboratories) and the ddCt method 
was employed with normalization to GAPDH [40]. 
Primer sequences are available upon request. 
Mouse tumor assays
All animal studies were approved by the Dartmouth 
IACUC under protocol spin.mj.1. For mouse studies, 
5–8 week old male athymic nude mice (Charles River) 
were injected subcutaneously in the flank with 5 × 106 
cisplatin resistant NT2/D1-R1 cells after resuspension in a 
50:50 ratio of DMEM/Matrigel (Corning). Once palpable 
tumors were detected, tumor volume was measured every 
two days with calipers using the formula V= (L × W × 
W)/2. Guadecitabine was diluted in PBS and delivered 
by subcutaneous injection. Cisplatin was delivered by 
intraperitoneal injection. 
Gene expression microarray analysis
Tumors were dissected free from stroma and 
mouse tissue, washed in PBS and immediately placed in 
RNAlater (Thermo Fisher Scientific).  RNA was extracted 
using an RNeasy Mini Kit (Qiagen) and quality control 
was performed with the Agilent Bioanalyzer and RNA 
was quantified with the Qubit Fluorometer (Thermo Fisher 
Scientific) and stored at -80oC.  Expression analysis was 
performed in triplicate with the Illumina HumanHT-12 v4 
bead chip arrays (Illumina) and scanned on the BeadArray 
Reader (Illumia) according to the manufacturer’s 
instructions.  Raw data were normalized (quantile) and 
analyzed with Genome Studio software (Illumina). GSEA 
software was downloaded from the Broad website (http://
www.broadinstitute.org/gsea/index.jsp). The number of 
permutations was 1,000 and the permutation type was 
gene_set.  Gene expression microarray data has been 
submitted to the NCBI GEO repository as GSE90681.
Statistics
When a value for statistical significance is provided, 
a two-sample, one-tailed t-test assuming unequal variance 
was performed.
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